Harvard Heart Letter

Ask the doctor: Should I try one of the new blood thinners?

Although new blood thinners such as dabigatran (Pradaxa) and rivaroxaban (Xarelto) do not require regular monitoring, people who manage well on warfarin may want to stay on warfarin until additional information on these new drugs becomes available.

To continue reading this article you must be registered.

Get Licensed Content to Harvard Health

If you are interested in licensing content from Harvard Health Publications, please contact us using our online form. Our licensing and business development professionals will help you leverage consumer health content from Harvard Medical School as a clear differentiator in helping achieve your business goals.

Contact Us

Customer Log In